|10-03-2002, 12:55 PM||#1|
Join Date: Jul 2001
Aastrom Biosciences and Stanford University Collaborate on Experimental Treatment For Multiple Myeloma
Aastrom Biosciences and Stanford University Collaborate on Experimental Treatment For Multiple Myeloma- Clinical Study Uses New Dendritic Cell Vaccine Approach -
ANN ARBOR, Mich., Oct 2, 2002
/PRNewswire-FirstCall via COMTEX/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today the initiation of a collaborative agreement with Leland Stanford Junior University (Stanford) for an immunotherapeutic vaccine clinical study for multiple myeloma cancer patients. The collaboration will combine Aastrom's dendritic cell vaccine technology with Stanford's cancer antigen technology to produce a cell-based treatment for multiple myeloma.
The clinical study will be conducted at Stanford University Medical Center under the direction of Ronald Levy, M.D., Chief, Division of Oncology at Stanford University Medical Center. Dr. Levy is the principal investigator and received a grant supporting this study from the National Institutes of Health, Grant Number CA49605, Project 6, titled, "Idiotype Vaccination Following Allogeneic Transplantation For the Treatment of Multiple Myeloma."
"This collaboration represents an important development for Aastrom, as it moves our dendritic cell technology forward into the clinic in a very interesting format," stated Steven Wolff, M.D., Vice President Medical Research at Aastrom. "Dr. Levy's protocol will attempt to harness the power of the immune system to attack a serious form of cancer. Aastrom's dendritic cell technology has been developed to provide the cells for this type of clinical approach."
Dendritic cells are found in the skin, lymphoid tissues and the blood, and are the most potent antigen-presenting cell serving to initiate an immune reaction. Antigens are biological molecules that combine with dendritic cells. These antigen-loaded dendritic cells "educate" immune system T-cells to recognize antigens on target cells. This approach can be used to form a tumor-specific vaccine, by first producing a specific class of dendritic cells using cell culture, and then loading these cells with antigen that is specific to a patient's tumor. Once administered to cancer patients, these dendritic cell vaccines are intended to work by triggering a T-cell immune system response against the patient's tumor cells. Recent research publications have shown encouraging data and results with these new therapeutic vaccines in renal cell carcinoma, melanoma, prostate and other cancers. The Aastrom/Stanford collaboration will extend this approach to multiple myeloma.
About Aastrom Biosciences, Inc.
Aastrom develops unique cell-based products through proprietary technologies for stem cell tissue repair, and the treatment of cancer and infectious disease. These competencies are based on dual-technology platforms: patented single-pass perfusion (SPP), providing cells with excellent biological function, and patented GMP-compliant system automation facilitating the delivery of cells for therapeutic use in medical practice.
These technologies are integrated into the AastromReplicell(TM) System, to uniquely standardize and automate the processes involved in producing high quality Tissue Repair Cells (TRCs) and Therapeutic Cells (TCs). Aastrom's growing pipeline of TRC products, derived from bone marrow and cord blood, target the reconstruction of normal tissues. These TRCs are intended for use in stem cell transplants, the treatment of severe osteoporosis and in bone grafting procedures.
Aastrom also has an expanding line of potential TC products. These TCs are intended to function similarly to drugs in causing a therapeutic action. Aastrom's TC products under development include the Dendricell(TM) dendritic cell products for the cancer vaccine market. In addition, Aastrom has developed a proprietary cell manufacturing device, the AastromReplicell(TM) System. These products are not available for sale at this time in the U.S., except for research or investigational use. The SC-I, CB-I, DC-I, DCV-I cell production products and the
AastromReplicell(TM) System are CE Mark approved for European marketing and sales, and the System is also available to clinical research programs and companies developing cell therapies.
Please visit our website at http://www.aastrom.com
This document contains forward-looking statements, including without limitation, statements regarding product development objectives, potential product applications and potential advantages of the AastromReplicell(TM) System and related cell therapy kits, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "intend," "potential," "can," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the results obtained from clinical trial and development activities, research activities being conducted by others, regulatory approval requirements, the availability of resources, competitive developments and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K, and other filings with the Securities and Exchange Commission.
CONTACTS: Kris M. Maly Investor Relations Manager Aastrom Biosciences, Inc. Phone: (734) 930-5777
Noonan Russo Presence Euro RSCG Brian Ritchie, Phone: (212) 845-4269 (media) David Walsey, Phone: (212) 845-4257 (investors)
The Scottsdale Group Susan Ladue, Phone: (781) 292-1050